Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq, Sophie
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. [electronic resource] - Trials Dec 2019 - 739 p. digital
Publication Type: Clinical Trial Protocol; Journal Article
1745-6215
10.1186/s13063-019-3767-8 doi
Administration, Cutaneous
Adolescent
Adult
Child
Clinical Trials, Phase II as Topic
Dermatologic Agents--administration & dosage
Double-Blind Method
France
Humans
Lymphangiectasis--drug therapy
Lymphatic Abnormalities--drug therapy
Multicenter Studies as Topic
Quality of Life
Randomized Controlled Trials as Topic
Sirolimus--administration & dosage
Skin Diseases--drug therapy
TOR Serine-Threonine Kinases--metabolism
Treatment Outcome
Young Adult
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. [electronic resource] - Trials Dec 2019 - 739 p. digital
Publication Type: Clinical Trial Protocol; Journal Article
1745-6215
10.1186/s13063-019-3767-8 doi
Administration, Cutaneous
Adolescent
Adult
Child
Clinical Trials, Phase II as Topic
Dermatologic Agents--administration & dosage
Double-Blind Method
France
Humans
Lymphangiectasis--drug therapy
Lymphatic Abnormalities--drug therapy
Multicenter Studies as Topic
Quality of Life
Randomized Controlled Trials as Topic
Sirolimus--administration & dosage
Skin Diseases--drug therapy
TOR Serine-Threonine Kinases--metabolism
Treatment Outcome
Young Adult